Aspen Neuroscience

News

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

News

Anthropic sets out its biopharma ambitions in IPO doc

Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."

News

Bambusa, Aspen, and Tang added to IPO pipeline

2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.

News

ADC specialist Solve raises $120m, and other biofinancings

Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.

News

Aspen taps tech firms for digital Parkinson's trial

Aspen Neuroscience is adding a digital dimension to a study of its experimental cell therapy for Parkinson's disease, with the help of tech companies Emerald Innovations a

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Anthropic sets out its biopharma ambitions in IPO doc

Bambusa, Aspen, and Tang added to IPO pipeline

ADC specialist Solve raises $120m, and other biofinancings

Aspen taps tech firms for digital Parkinson's trial

Oral Wegovy bolsters Novo in Q3

Discover a new era of healthcare panel engagement: Grounded ...

Aspen Neuroscience

Editor's Picks